William Hughes, DO
Sports Medicine · Louisville, KYNPI 1912266305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 79.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $243 and has fallen 80.9% since, to $46 in 2025. That places this record below the midpoint for sports medicine clinicians in KY, where the typical reported total is $625.
Across 45 payments — averaging $11.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$408
- Johnson & Johnson$33
- Pacira Pharmaceuticals Incorporated$28
- Novo Nordisk$20
- AbbVie$14
- Alpha Orthopedic Systems$11
What the payments were for
- Food & beverage$515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 39 | $408 |
| Johnson & Johnson | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
| Novo Nordisk | 1 | $20 |
| AbbVie | 1 | $14 |
| Alpha Orthopedic Systems | 1 | $11 |
How this compares
$515 in reported general payments places this provider in the 40th percentile of 59 sports medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $2,421 |
| Celecoxib | 44 | $1,622 |
| Rosuvastatin Calcium | 75 | $872 |
| Atorvastatin Calcium | 100 | $654 |
| Gabapentin | 49 | $589 |
| Meloxicam | 33 | $577 |
| Metoprolol Succinate | 40 | $543 |
| Duloxetine Hcl | 14 | $465 |
| Trazodone Hcl | 18 | $327 |
| Levothyroxine Sodium | 35 | $321 |
| Pantoprazole Sodium | 12 | $266 |
| Lisinopril | 52 | $258 |
| Omeprazole | 25 | $239 |
| Metformin Hcl | 34 | $236 |
| Losartan Potassium | 36 | $212 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Louisville
- Ryan KruppLouisville$803K
- Neil PatilLouisville$5K
- Scotty NewcomerLouisville$2K
- Paul McKeeLouisville$2K
- Gregory PottsLouisville$1K
- Robin CurryLouisville$1K
- Jordan HilgefortLouisville$758
- Nathan McKinneyLouisville$686
- Mark PuckettLouisville$620
- Joshua WuLouisville$615
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.